issued
on 20 Feb 2024
Last Applicant/ Owned by
17383 Sunset Blvd., Suite A250
Pacific Palisades
CA
90272
Serial Number
97518236 filed on 25th Jul 2022
Registration Number
N/A
Correspondent Address
Chelsea E. Carbone
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research sRead More
Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of drug discovery process development, drug discovery validation, drug discovery qualification, and drug discovery manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation and testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation and testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases
Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular disease, epilepsy and mitochondrial disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in the treatment of diseases and disorders in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in pediatric, geriatric, emergency, family, and human preventative medicine for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease; pharmaceutical preparations for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease
No 97518236
No Service Mark
No 45455-TM1027
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 20th Feb 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 08th Jan 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 08th Jan 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 08th Jan 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 26th Dec 2023 | PUBLISHED FOR OPPOSITION |
| 26th Dec 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 06th Dec 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 21st Nov 2023 | EXAMINERS AMENDMENT -WRITTEN |
| 21st Nov 2023 | EXAMINERS AMENDMENT E-MAILED |
| 21st Nov 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
